US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Voyager Acquisition Corp

10.37

+0.01000.10%

Volume:13.78K

Turnover:142.98K

Market Cap:327.95M

PE:35.08

High:10.38

Open:10.38

Low:10.36

Close:10.36

Loading ...

Overview Company News Filings

VERAXA Biotech to Attend Key Industry Conferences to Showcase BiTAC Technology Platform

OmniAb, Veraxa Biotech Partner on Solid Tumor Drug Discovery Program

MT Newswires Live

VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program

Voyager Acquisition, VERAXA Biotech to Merge, Creating $1.64 Billion Public Cancer Therapy Company

MT Newswires Live

Swiss biotech firm Veraxa to list on Nasdaq in $1.64 billion SPAC deal

Veraxa Biotech to merge with SPAC Voyager in $1.64 billion deal

BRIEF-Xlife Sciences AG Says Veraxa Biotech AG To Merge With Voyager Acquisition Corp.

Voyager Acquisition Corp - Transaction Values Veraxa at $1.3 Billion Pre-Money Equity Value

THOMSON REUTERS

Veraxa Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies

THOMSON REUTERS

Press Release: VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/VACH/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"VACH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VACH\",,,,,undefined,":{"symbol":"VACH","market":"US","secType":"STK","nameCN":"Voyager Acquisition Corp","latestPrice":10.37,"timestamp":1749585600000,"preClose":10.36,"halted":0,"volume":13779,"delay":0,"floatShares":20965781,"shares":31625000,"eps":0.295619,"marketStatus":"Post-Mkt","change":0.01,"latestTime":"06-10 17:50:13 EDT","open":10.38,"high":10.38,"low":10.36,"amount":142978.3962,"amplitude":0.001931,"askPrice":12.54,"askSize":100,"bidPrice":9.33,"bidSize":100,"shortable":3,"etf":0,"ttmEps":0.295619,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1749600000000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":10.36,"preHourTrading":{"tag":"盘前","latestPrice":11.37,"preClose":10.36,"latestTime":"09:17 EDT","volume":100,"amount":1137,"timestamp":1749561441894},"volumeRatio":1.919776},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VACH\",,,,,undefined,":{"symbol":"VACH","floatShares":20965781,"roa":"--","roe":"--","lyrEps":0.264862,"volumeRatio":1.919776,"shares":31625000,"dividePrice":0,"high":10.38,"amplitude":0.001931,"preClose":10.36,"low":10.36,"week52Low":9.95,"pbRate":"-28.20","week52High":11.2,"institutionHeld":0,"latestPrice":10.37,"eps":0.295619,"divideRate":0,"volume":13779,"delay":0,"ttmEps":0.295619,"open":10.38,"prevYearClose":10.02,"prevWeekClose":10.36,"prevMonthClose":10.31,"prevQuarterClose":10.18,"fiveDayClose":10.33,"twentyDayClose":10.295,"sixtyDayClose":10.16},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"VACH\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2539822910","title":"VERAXA Biotech to Attend Key Industry Conferences to Showcase BiTAC Technology Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2539822910","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539822910?lang=en_us&edition=fundamental","pubTime":"2025-05-30 06:34","pubTimestamp":1748558040,"startTime":"0","endTime":"0","summary":"VERAXA Attending ASCO and BIO with Cantor Fitzgerald, Voyager's Recently Retained Capital Markets Advisor, and Hosting Meetings with Potential Partners and InvestorsZURICH, May  29, 2025  (GLOBE NEWSW","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/05/29/3090786/0/en/VERAXA-Biotech-to-Attend-Key-Industry-Conferences-to-Showcase-BiTAC-Technology-Platform.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CEO","CBO","VACH"],"gpt_icon":0},{"id":"2533553170","title":"OmniAb, Veraxa Biotech Partner on Solid Tumor Drug Discovery Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2533553170","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533553170?lang=en_us&edition=fundamental","pubTime":"2025-05-06 01:23","pubTimestamp":1746465807,"startTime":"0","endTime":"0","summary":"Voyager Acquisition's (VACH) planned merger target Veraxa Biotech on Monday said it entered a co-discovery alliance with OmniAb (OABI) to develop a bispecific antibody drug conjugate targeting solid t","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OABI","BK4121","VACH"],"gpt_icon":0},{"id":"2533558142","title":"VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2533558142","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533558142?lang=en_us&edition=fundamental","pubTime":"2025-05-06 00:59","pubTimestamp":1746464340,"startTime":"0","endTime":"0","summary":"Partnership Combines VERAXA's Proprietary ADC Technology with OmniAb's Antibody Discovery Technology for Novel Therapies Targeting Solid Tumors. ZURICH, SWITZERLAND, May 05, 2025  -- VERAXA Biotech AG , an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target ofVoyager Acquisition Corp. , announced today a co-discovery alliance with OmniAb, Inc.  for the development of a novel bispecific antibody drug conjugate  program targeting solid tumors. The collaboration brings together OmniAb’s suite of transgenic antibody discovery solutions with VERAXA’s proprietary antibody drug conjugate  linker technology and conjugation expertise to support next-generation therapeutic discovery.At VERAXA, we are building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific ADCs, bispecific T cell engagers and other innovative formats. Powered by a suite of transformative technologies and guided by rigo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/veraxa-biotech-enters-co-discovery-165900881.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["VACHW","VACHU","QLD","USAW.SI","OABIW","PSQ","QID","TSYW.SI","USJW.SI","VACH","NQmain",".IXIC","NVIW.SI","TQQQ","SQQQ","BK4121","MNQmain","OABI"],"gpt_icon":1},{"id":"2529238715","title":"Voyager Acquisition, VERAXA Biotech to Merge, Creating $1.64 Billion Public Cancer Therapy Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2529238715","media":"MT Newswires Live","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529238715?lang=en_us&edition=fundamental","pubTime":"2025-04-23 15:57","pubTimestamp":1745395042,"startTime":"0","endTime":"0","summary":"Voyager Acquisition  and VERAXA Biotech have agreed to merge, forming a publicly traded, clinical-stage biopharma company focused on next-gen cancer treatments, the companies said Wednesday.The companies said that post-merger, VERAXA will trade on the Nasdaq under the ticker 'VERX.'The deal values VERAXA at $1.3 billion, with shareholders receiving 130 million shares in the new entity, the companies said, adding no cash proceeds will go to existing VERAXA shareholders, who will roll over their equity.Assuming a $10 per share valuation and no Voyager shareholder redemptions, the combined company's implied equity value is $1.64 billion, they added.VERAXA may gain access to up to $253 million in cash held by Voyager, pending transaction costs and shareholder approvals, the companies said.They added that VERAXA is also raising additional funds to support operations for the next two years.The merger is expected to close in Q4.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["VACH"],"gpt_icon":0},{"id":"2529149545","title":"Swiss biotech firm Veraxa to list on Nasdaq in $1.64 billion SPAC deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2529149545","media":"Reuters","labels":["shareholding","corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529149545?lang=en_us&edition=fundamental","pubTime":"2025-04-23 13:50","pubTimestamp":1745387450,"startTime":"0","endTime":"0","summary":"UPDATE 2-Swiss biotech firm Veraxa to list on Nasdaq in $1.64 billion SPAC dealAdds details throughoutBERLIN, April 23  - Swiss biotech investor Xlife Sciences AG XLS.S said on Wednesday its portfolio company Veraxa Biotech AG would list on U.S. exchange Nasdaq in a $1.64 billion merger deal with a special-purpose acquisition vehicle, or SPAC.The planned merger with the SPAC Voyager Acquisition VACH.O values Veraxa, cancer drug developer, at about $1.3 billion excluding trust funds, Xlife said in a statement. Assuming a share price of $10 and full participation of the investors behind Voyager, the implied pro-forma equity value of the combined entity will be about $1.64 billion, it said. Upon expected completion of the transaction in the fourth quarter, Veraxa stands to receive gross proceeds of up to $253 million in Voyager's trust account, Xlife said. Veraxa, based in Switzerland, runs research and development facilities in Heidelberg, Germany, and it is already testing drug candidat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250423:nL4N3R10F9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding,corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VACH"],"gpt_icon":0},{"id":"2529548173","title":"Veraxa Biotech to merge with SPAC Voyager in $1.64 billion deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2529548173","media":"Reuters","labels":["shareholding","corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529548173?lang=en_us&edition=fundamental","pubTime":"2025-04-23 13:19","pubTimestamp":1745385591,"startTime":"0","endTime":"0","summary":"Veraxa Biotech to merge with SPAC Voyager in $1.64 billion dealApril 23  - Switzerland's Xlife Sciences AG XLS.S said on Wednesday its portfolio company, VERAXA Biotech AG, will merge with Voyager Acquisition VACH.O in a deal that will value the combined company at $1.64 billion.   ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250423:nL4N3R10EM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VACH"],"gpt_icon":0},{"id":"2529839548","title":"BRIEF-Xlife Sciences AG Says Veraxa Biotech AG To Merge With Voyager Acquisition Corp.","url":"https://stock-news.laohu8.com/highlight/detail?id=2529839548","media":"Reuters","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529839548?lang=en_us&edition=fundamental","pubTime":"2025-04-23 13:07","pubTimestamp":1745384847,"startTime":"0","endTime":"0","summary":"BRIEF-Xlife Sciences AG Says Veraxa Biotech AG To Merge With Voyager Acquisition Corp. April 23 (Reuters) - Xlife Sciences AG XLS.S:FROM LAB TO UNICORN: XLIFE SCIENCES AG PORTFOLIO COMPANY VERAXA BIOT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250423:nTUC1RG50C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VACH"],"gpt_icon":0},{"id":"2529782510","title":"Voyager Acquisition Corp - Transaction Values Veraxa at $1.3 Billion Pre-Money Equity Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2529782510","media":"THOMSON REUTERS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529782510?lang=en_us&edition=fundamental","pubTime":"2025-04-23 13:00","pubTimestamp":1745384402,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250423:nTUABKMFNW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VACHW","VACH"],"gpt_icon":0},{"id":"2529261510","title":"Veraxa Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2529261510","media":"THOMSON REUTERS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529261510?lang=en_us&edition=fundamental","pubTime":"2025-04-23 13:00","pubTimestamp":1745384402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250423:nTUABKMFNW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VACH","VACHW"],"gpt_icon":0},{"id":"2529510903","title":"Press Release: VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2529510903","media":"Dow Jones","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529510903?lang=en_us&edition=fundamental","pubTime":"2025-04-23 13:00","pubTimestamp":1745384400,"startTime":"0","endTime":"0","summary":"VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies. -- VERAXA's Novel BiTAC Platform has the Potential to Deliver Multiple. -- Company Pursuing Multiple Strategic Partnerships and Licensing. -- Transaction Values VERAXA at a Pre-money Equity Value of $1.3 Billion. -- Actively Working with Existing and New VERAXA Investors to Raise a. Business Combination, Alongside up to $253 Million in Cash Held in Trust. -- Business Combination is Expected to be Completed in the Fourth Quarter of. VERAXA is advancing a premier drug discovery and development engine for ADCs and other novel antibody-based therapy concepts. Through Bi-Targeted Antibody Cytotoxicity , a powerful and scalable proprietary technology platform that enables a highly specific dual-marker approach, the Company is accelerating a pipeline of next-generation cancer therapies that have the pot","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2210150020.SGD","IE00B3QW5Z07.USD","PSQ","BK4585","NDAQ","IE00B64PRP62.GBP","VACH","TSYW.SI","IE00BKPKM429.USD","TQQQ","NQmain","MNQmain","QLD","SQQQ","BK4588","IE00BGHQF748.EUR","QID","USAW.SI",".IXIC","LU2095319765.USD","USJW.SI","LU2210149790.SGD","NVIW.SI"],"gpt_icon":1}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":10,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/VACH\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-15","symbol":"VACH","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"VACH\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"VACH\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/VACH\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"VACH","date":"2025-06-09","current":49.442727,"percent":0.07177,"low":49.108655,"twenty":74.297135,"median":76.592691,"eighty":77.661782,"high":78.730872,"avg":74.200637,"sd":7.6622,"marketCap":327635000},"quantilePoints":[{"date":"2024-08-09","current":66.403131,"twenty":66.403131,"median":66.403131,"eighty":66.403131,"marketCap":275000000},{"date":"2024-08-16","current":74.222763,"twenty":66.323447,"median":66.403131,"eighty":74.222763,"marketCap":307384000},{"date":"2024-08-23","current":74.259949,"twenty":66.403131,"median":74.222763,"eighty":74.222763,"marketCap":307538000},{"date":"2024-08-30","current":74.185578,"twenty":66.403131,"median":74.204171,"eighty":74.222763,"marketCap":307230000},{"date":"2024-09-06","current":74.371506,"twenty":67.952183,"median":74.222763,"eighty":74.222763,"marketCap":308000000},{"date":"2024-09-13","current":74.297135,"twenty":74.155829,"median":74.222763,"eighty":74.282558,"marketCap":307692000},{"date":"2024-09-20","current":74.371506,"twenty":74.185578,"median":74.222763,"eighty":74.297135,"marketCap":308000000},{"date":"2024-09-27","current":74.371506,"twenty":74.185578,"median":74.222763,"eighty":74.371506,"marketCap":308000000},{"date":"2024-10-04","current":76.210873,"twenty":74.193015,"median":74.274079,"eighty":74.371506,"marketCap":315617500},{"date":"2024-10-11","current":76.3636,"twenty":74.222763,"median":74.297135,"eighty":75.781909,"marketCap":316250000},{"date":"2024-10-18","current":76.516328,"twenty":74.222763,"median":74.315728,"eighty":76.210873,"marketCap":316882500},{"date":"2024-10-25","current":76.516328,"twenty":74.222763,"median":74.371506,"eighty":76.348327,"marketCap":316882500},{"date":"2024-11-01","current":76.516328,"twenty":74.222763,"median":74.371506,"eighty":76.428051,"marketCap":316882500},{"date":"2024-11-08","current":76.516328,"twenty":74.222763,"median":74.371506,"eighty":76.501055,"marketCap":316882500},{"date":"2024-11-15","current":76.592691,"twenty":74.222763,"median":74.371506,"eighty":76.516328,"marketCap":317198750},{"date":"2024-11-22","current":76.500291,"twenty":74.222763,"median":76.13451,"eighty":76.516328,"marketCap":316816087},{"date":"2024-11-29","current":76.516328,"twenty":74.222763,"median":76.210873,"eighty":76.516328,"marketCap":316882500},{"date":"2024-12-06","current":76.516328,"twenty":74.222763,"median":76.249055,"eighty":76.516328,"marketCap":316882500},{"date":"2024-12-13","current":76.666,"twenty":74.222763,"median":76.3636,"eighty":76.516328,"marketCap":317502350},{"date":"2024-12-20","current":76.516328,"twenty":74.222763,"median":76.372,"eighty":76.516328,"marketCap":316882500},{"date":"2024-12-27","current":76.554509,"twenty":74.252512,"median":76.439964,"eighty":76.516328,"marketCap":317040625},{"date":"2025-01-03","current":76.745418,"twenty":74.276906,"median":76.439964,"eighty":76.516328,"marketCap":317831250},{"date":"2025-01-10","current":76.979854,"twenty":74.29178,"median":76.439964,"eighty":76.554509,"marketCap":318802137},{"date":"2025-01-17","current":77.2036,"twenty":74.297135,"median":76.500291,"eighty":76.592691,"marketCap":319728750},{"date":"2025-01-24","current":76.974509,"twenty":74.297135,"median":76.516328,"eighty":76.592691,"marketCap":318780000},{"date":"2025-01-31","current":76.898146,"twenty":74.297135,"median":76.516328,"eighty":76.593302,"marketCap":318463750},{"date":"2025-02-07","current":77.037127,"twenty":74.304572,"median":76.516328,"eighty":76.669055,"marketCap":319039325},{"date":"2025-02-14","current":77.432691,"twenty":74.341758,"median":76.516328,"eighty":76.898146,"marketCap":320677500},{"date":"2025-02-21","current":77.279964,"twenty":74.371506,"median":76.516328,"eighty":76.898146,"marketCap":320045000},{"date":"2025-02-28","current":77.585418,"twenty":74.371506,"median":76.516328,"eighty":76.974509,"marketCap":321310000},{"date":"2025-03-07","current":77.738145,"twenty":74.371506,"median":76.516328,"eighty":76.979854,"marketCap":321942500},{"date":"2025-03-14","current":77.585418,"twenty":74.371506,"median":76.516328,"eighty":77.127236,"marketCap":321310000},{"date":"2025-03-21","current":77.890872,"twenty":74.371506,"median":76.516328,"eighty":77.2036,"marketCap":322575000},{"date":"2025-03-28","current":77.967236,"twenty":74.371506,"median":76.516328,"eighty":77.2036,"marketCap":322891250},{"date":"2025-04-04","current":77.890872,"twenty":74.371506,"median":76.516328,"eighty":77.279964,"marketCap":322575000},{"date":"2025-04-11","current":78.27269,"twenty":74.371506,"median":76.554509,"eighty":77.279964,"marketCap":324156250},{"date":"2025-04-17","current":77.967236,"twenty":74.371506,"median":76.592691,"eighty":77.3716,"marketCap":322891250},{"date":"2025-04-25","current":78.27269,"twenty":74.371506,"median":76.592691,"eighty":77.524327,"marketCap":324156250},{"date":"2025-05-02","current":78.578145,"twenty":75.781909,"median":76.592691,"eighty":77.585418,"marketCap":325421250},{"date":"2025-05-09","current":78.578145,"twenty":76.13451,"median":76.592691,"eighty":77.677055,"marketCap":325421250},{"date":"2025-05-16","current":49.204104,"twenty":75.781909,"median":76.592691,"eighty":77.738145,"marketCap":326053750},{"date":"2025-05-23","current":49.204104,"twenty":74.371506,"median":76.592691,"eighty":77.738145,"marketCap":326053750},{"date":"2025-05-30","current":49.204104,"twenty":74.371506,"median":76.592691,"eighty":77.692327,"marketCap":326053750},{"date":"2025-06-06","current":49.548676,"twenty":74.319447,"median":76.592691,"eighty":77.661782,"marketCap":328337075},{"date":"2025-06-09","current":49.442727,"twenty":74.297135,"median":76.592691,"eighty":77.661782,"marketCap":327635000}],"updateTime":1749570496141}}}